1 – 10 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Cost of Illness of Head and Neck Cancer in Sweden
2024) In Value in Health(
- Contribution to journal › Article
- 2023
-
Mark
Economic Evaluation of Elective Cesarean Section on Maternal Request Compared With Planned Vaginal Birth—Application to Swedish Setting Using National Registry Data
(
- Contribution to journal › Article
- 2022
-
Mark
The Value of Nonpharmacological Interventions for People With an Acquired Brain Injury: : A Systematic Review of Economic Evaluations
(
- Contribution to journal › Scientific review
-
Mark
The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020 : A Review
(
- Contribution to journal › Article
- 2016
-
Mark
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease : Are Current Models Suitable to Evaluate Personalized Medicine?
(
- Contribution to journal › Article
- 2015
-
Mark
The Cost of Treating Recurrent Clostridium Difficile Infection In Patients Attending Infectious Disease Clinics At Four Hospitals In Sweden.
(
- Contribution to journal › Article
-
Mark
Applying Weighted Cumulative Exposure Models to Patterns of Nonspecific Symptom Consultations for Early Diagnosis: A Primary Care Database Study of Knee Pain and Osteoarthritis.
(
- Contribution to journal › Article
-
Mark
The Prostate Cancer Registry: Analysis of Medical Resource Utilisation (Mru) in An International, Prospective, Observational Study of Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc).
(
- Contribution to journal › Article
-
Mark
Hexaminolevulinate Blue-Light Flexible Cystoscopy In Addition To Standard White-Light Cystoscopy In The Follow-Up Of Non-Muscle Invasive Bladder Cancer: Cost-Consequences During Outpatient Surveillance In Sweden
(
- Contribution to journal › Article
- 2014
-
Mark
Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
(
- Contribution to journal › Article